导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.57% | 3226/4773 |
| 近一周 | -1.53% | 1245/5458 |
| 近一月 | -6.27% | 3635/5421 |
| 近一季 | 7.98% | 229/5205 |
| 近半年 | -2.31% | 2070/4920 |
| 近一年 | -15.64% | 3763/4361 |
| 近两年 | 16.67% | 2726/2954 |
| 近三年 | -10.45% | 2055/2253 |
| 成立以来 | -40.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.68% 2426/4961 |
-6.44% 3696/5312 |
- - |
- - |
| 2025 | 4.82% 3028/4813 |
0.66% 1798/3635 |
1.85% 2084/4076 |
16.17% 2703/4524 |
-11.99% 4227/4813 |
| 2024 | -12.48% 2382/3463 |
-10.82% 2384/2808 |
-9.04% 2318/3014 |
18.64% 973/3129 |
-9.06% 2900/3463 |
| 2023 | -10.75% 1330/2656 |
0.14% 1760/2280 |
-7.34% 1838/2385 |
-1.47% 527/2515 |
-2.38% 467/2655 |
| 2022 | -20.28% 955/2207 |
-12.58% 637/1919 |
0.25% 1573/2016 |
-16.46% 1460/2113 |
8.89% 249/2208 |
| 2021 | -10.92% 1098/1822 |
-3.19% 775/1255 |
13.97% 271/1330 |
-15.15% 1380/1466 |
-4.85% 1499/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 鹏华中证医药卫生(LOF)C VS. 长安沪深300非周期A(740101) |